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Introduction
• Approx 300,000 heart valve replacements are
performed annually however, current treatment
options have limited success.
• Current therapies cannot grow or remodel with the
patient. These shortcomings have prompted
increased focus on tissue engineering techniques to
create fully autologous heart valve replacements.
• Despite significant advances in the field of heart
valve tissue engineering, a major problem is the
inability of valves to maintain an appropriate seal
upon closure as a result of cell-mediated retraction
of the leaflets [1].
Figure 1. This image shows a
native aortic valve (taken
from the arterial side) [2]
where the leaflets form a
closed seal. In cases of heart
valve disease the shape or
elasticity of the leaflets
prevents this seal forming
which means that there is a
leakage of blood through the
valve.

Materials and methods

Results

• Scaffolds
were
crosslinked
physically
by
dehydrothermal (DHT) cross-linking at 105ºC for 24
hours. They were subsequently chemically crosslinked
using 1-Ethyl-3-(3-dimethyl aminopropyl) carbodiimide
(EDAC) in the presence of N-hydroxysuccinimide
(NHS), solution which stiffens the scaffold while
maintaining elasticity [7].

• Drop loading resulted in a layer of fibrin being
established on the edges of the material due to the
rapid polymerisation time of fibrin. Injection of the
fibrin solution allowed for an even distribution of
polymerised fibrin throughout the material as
demonstrated in the SEM image shown.

• To infiltrate the CG material with fibrin (a four stage
solution which polymerises once the final ingredient is
added), both drop loading and injection methods were
assessed.
• Masson’s Trichrome staining and SEM were used to
assess the distribution of the fibrin throughout the CG
material.
• Mechanical properties were tested using a Zwick/Roell
Z050 testing machine.

Results
• Successful development of a freeze dried CG
material with a homogenous structure in a tri- leaflet
valve conduit shape.

• This study has led to the development of a freezedried CG-fibrin scaffold which will be used for heart
valve tissue engineering.

Figure 3. The image above shows the CG freeze
dried construct. Through optimisation of the freeze
drying process, a tri-leaflet valve was fabricated.

• A CG scaffold will be fabricated through freeze drying in
a 3-D mould (Figure 2).

Figure 2. We have
previously developed a
mould
for
the
construction
of
trileaflet
heart
valve
conduits [1,4,5] This
mould was modified for
producing freeze-dried
CG scaffolds.

• The stable ratio of fibrin to CG has been established
at 0.7μl per mm3 CG.
• A method of injecting the fibrin into the CG has been
developed which has demonstrated full infiltration of
the fibrin through the CG.

Figure 4. Masson’s Trichrome staining was used to
assess the pore size and porosity of the scaffolds
produced using a variety of freeze drying
parameters. This image shown is from the
optimised set of parameters. It shows a
homogenous pore structure with an average pore
size of 128.9 39.3μm and a porosity of 99.2%
Analysis was completed at the top, in the middle
leaflet section and at the lower section of the
scaffold.

• We successfully developed of a method of infiltrating
the CG scaffold with fibrin using an injection
technique. Through optimisation of fibrin infiltration,
a final volume of 0.7μl of fibrin gel per mm3 of CG
was established as the most stable ratio.
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• The use of crosslinking has been found to increase
the compressive and tensile moduli of the material
backbone which will improve the ability of the
material to withstand the contractile forces of the
cells on the material.

On-going Work
• The next phase of this study is to introduce cells to the
scaffold in order to assess the biological performance
of the material. This will also demonstrate the
resistance of the material to the contractile forces
exerted by the cells.
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• Freeze drying parameters such as final freezing
temperature, cooling rate and drying times were
optimised to produce a CG scaffold with a homogenous
pore size structure [6].
• The freeze drying cycle optimisation was assessed
using SEM, pore size and porosity analysis.

• This CG scaffold has a homogeneous pore structure
throughout and can be manufactured in a
repeatable, 3-D form.
• The proof of principle that fibrin can be successfully
infiltrated into the CG material has been
demonstrated.

• Hypothesis: A CG-fibrin scaffold will provide sufficient
structural stiffness to resist the contractile forces of
cells.

Materials and methods

Figure 6. SEM image of freeze-dried CG material
(A), infiltrated with fibrin (B) using an injection
method.

Discussion and conclusions

Aims and objectives

• Aim of this study: Develop a method of fabricating the
CG-fibrin scaffold and analyse the resulting material.
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• The tensile and compressive moduli of the materials
were also tested and the crosslinking greatly
enhanced the stiffness of the material.

• We are currently investigating natural biomaterials
(collagen, glycosaminoglycans (GAGs) and fibrin)
for the development of a scaffold which will have
sufficient stiffness to resist the contractile forces of
cells acting upon it.

• The novel scaffold proposed is based around the
concept of reinforcing cell-seeded fibrin gel
component [3] with a collagen-GAG (CG) matrix.
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